What drove the significant revenue growth in the third quarter?

Revenue growth was primarily driven by a 24% increase in total product sales, reaching $8.15 billion. This was fueled by strong volume growth across key products and the successful integration of products acquired from Horizon Therapeutics, notably TEPEZZA and KRYSTEXXA. Acquired Horizon products contributed $1.1 billion to product sales in the quarter.

Why did operating expenses increase significantly, and what is the impact on profitability?

Operating expenses increased by 32% to $6.46 billion. This rise is largely attributed to higher amortization expenses related to assets acquired in the Horizon transaction, along with increased spending on research and development and selling, general, and administrative activities. While revenue growth outpaced expense growth in the quarter, leading to a significant net income increase, investors should monitor the sustainability of this margin improvement given the ongoing expense pressures.

What is the status of Amgen's tax dispute with the IRS?

Amgen is actively contesting IRS claims related to profit allocation between its U.S. and Puerto Rico entities for the years 2010-2015. The IRS is seeking substantial additional federal tax, plus interest and penalties. The consolidated trial for the 2010-2012 and 2013-2015 periods is scheduled to begin in November 2024. Amgen believes its tax accruals are appropriate but acknowledges that an adverse outcome could materially impact its financial statements.

How is Amgen managing its debt and capital structure?

Amgen repaid $3.6 billion and extinguished $659 million in debt during the first nine months of 2024. The company also declared quarterly cash dividends of $2.25 per share. While cash and cash equivalents have decreased, Amgen believes its existing funds, cash generated from operations, and access to financing are adequate to meet its obligations, including debt service, capital expenditures, dividends, and potential strategic initiatives.

AMGN 10-Q Quarterly Report Q3 FY2024 — Revenue, Net Income, EPS

Summary

Amgen Inc. reported a significant increase in total revenues for the third quarter of 2024, reaching $8.5 billion, up 23% year-over-year. This growth was primarily driven by a substantial 24% increase in total product sales, largely attributable to the successful integration of products acquired from Horizon Therapeutics. Key products like Repatha, EVENITY, BLINCYTO, and TEZSPIRE showed strong volume growth. Despite the revenue surge, net income saw a notable 64% increase to $2.83 billion, with diluted EPS rising to $5.22, reflecting improved operational efficiency and strategic asset contributions. However, operating expenses also grew significantly, up 32% in the quarter, largely due to higher amortization related to acquisition-related assets and increased R&D and SG&A spending. The company also reported a decrease in cash and cash equivalents to $9.0 billion from $10.9 billion at the end of the prior year, primarily due to debt repayments and dividend payments, though the company maintains ample liquidity. Investors should note the ongoing substantial legal and tax contingencies, particularly the IRS tax dispute, which continue to pose potential risks despite Amgen's belief in its strong legal standing.

Financial Highlights

53 data points

Beta

Revenue

$8.50B

0.6% Gross Margin

Net Income

$2.83B

0.3% Net Margin

EPS (Diluted)

$5.22

Total Assets

$90.88B

Cash & Equivalents

$9.01B

Free Cash Flow

$3.31B

Financial Statements

Beta

Revenue	$8.50B
Cost of Revenue	$3.31B
Gross Profit	$5.19B
SG&A Expenses	$1.63B
Operating Expenses	$6.46B
Operating Income	$2.05B
Interest Expense	$776.00M
Net Income	$2.83B
EPS (Basic)	$5.27
EPS (Diluted)	$5.22
Shares Outstanding (Basic)	537.00M
Shares Outstanding (Diluted)	542.00M

Key Highlights

1Total revenues increased by 23% to $8.5 billion for the third quarter of 2024, compared to $6.9 billion in the prior year period.
2Product sales surged by 24% to $8.15 billion, driven by strong volume growth and contributions from acquired Horizon Therapeutics products.
3Net income increased by 64% to $2.83 billion, with diluted Earnings Per Share (EPS) rising to $5.22 from $3.22 in the prior year quarter.
4Operating expenses rose by 32% to $6.46 billion, primarily due to increased amortization from acquisition-related assets, R&D, and SG&A expenses.
5Cash and cash equivalents decreased to $9.01 billion as of September 30, 2024, from $10.94 billion as of December 31, 2023, impacted by debt repayment and dividend payments.
6The company is actively managing its debt, with significant repayments and extinguishments during the first nine months of 2024.
7Amgen continues to face and disclose significant legal and tax contingencies, notably the ongoing IRS tax dispute, which could materially impact future financial results.

AMGEN INC Quarterly Report for Q3 Ended Sep 30, 2024

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions